On Tuesday, Blueprint Medicines Corp (BPMC) stock saw a decline, ending the day at $90 which represents a decrease of $-2.50 or -2.70% from the prior close of $92.5. The stock opened at $91.63 and ...

Buy and Sell Signals for Blueprint Medicines Corporation BPMC that help investors manage their investment in BPMC ...

周四，Stifel重申了对Blueprint Medicines (NASDAQ:BPMC)股票的买入评级，目标价为155.00美元。该公司的评论强调了Blueprint Medicines在过敏和炎症市场的进展，特别是其主打产品Ayvakit的商业成功。

For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief ---- Approval based ...

Below is Validea's guru fundamental report for BLUEPRINT MEDICINES CORP (BPMC). Of the 22 guru strategies we follow, BPMC rates highest using our Quantitative Momentum Investor model based on the ...

On Friday, Blueprint Medicines Corp (BPMC) stock saw a modest uptick, ending the day at $92.55 which represents a slight increase of $3.49 or 3.92% from the prior close of $89.06. The stock opened at ...

Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the second quarter ended June 30, 2024, and provided updated financial guidance.

Stifel, a financial services company, increased its price target for Blueprint Medicines (NASDAQ: NASDAQ:BPMC) shares from $150 to $155 while maintaining a "Buy" rating on the ...

Driehaus Capital Management LLC boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 101.0% in the 2nd quarter, according to the company in its most recent 13F filing ...

After losing some value lately, a hammer chart pattern has been formed for Blueprint Medicines (BPMC), indicating that the stock has found support. This, combined with an upward trend in earnings ...

Short interest in Blueprint Medicines Corp (NASDAQ:BPMC) decreased during the last reporting period, falling from 4.05M to 3.96M. This put 7.05% of the company's publicly available shares short.